U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2015
471
Name Type Language
SECUKINUMAB
DASH   INN   USAN   WHO-DD  
USAN   INN  
Official Name English
AIN457
Code English
AIN-457
Code English
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS IL17A (INTERLEUKIN 17A, IL-17A)), HOMO SAPIENS MONOCLONAL ANTIBODY
Common Name English
COSENTYX
Brand Name English
SECUKINUMAB [USAN]
Common Name English
Secukinumab [WHO-DD]
Common Name English
AIN457A
Code English
SECUKINUMAB [JAN]
Common Name English
SECUKINUMAB [PURPLE BOOK CDER]
Common Name English
secukinumab [INN]
Common Name English
SECUKINUMAB [MI]
Common Name English
SECUKINUMAB (GENETICAL RECOMBINATION)
Official Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS COSENTYX (AUTHORIZED: ARTHRITIS, PSORIATIC)
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
WHO-ATC L04AC10
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
WHO-VATC QL04AC10
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
NDF-RT N0000191495
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
NCI_THESAURUS C574
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
NCI_THESAURUS C20401
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
FDA ORPHAN DRUG 281309
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
Code System Code Type Description
CAS
1229022-83-6
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
DAILYMED
DLG4EML025
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
NCI_THESAURUS
C152315
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
ChEMBL
CHEMBL1743068
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
SMS_ID
100000126309
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
JAPANESE REVIEW
COSENTYX (INITIAL APPROVAL)
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY APPROVED DECEMBER 2014
MERCK INDEX
m11827
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
USAN
XX-120
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
CAS
875356-43-7
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
ALTERNATIVE
EVMPD
SUB33242
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
WIKIPEDIA
Secukinumab
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
DRUG CENTRAL
4934
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
LACTMED
Secukinumab
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
RXCUI
1599788
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY RxNorm
NDF-RT
N0000191494
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY Interleukin-17A Antagonists [MoA]
INN
9182
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
JAPANESE REVIEW
COSENTYX (PARTIAL CHANGE APPROVAL)
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY APPROVED DECEMBER 2015
IUPHAR
8078
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
DRUG BANK
DB09029
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
FDA UNII
DLG4EML025
Created by admin on Sat Dec 16 01:55:12 UTC 2023 , Edited by admin on Sat Dec 16 01:55:12 UTC 2023
PRIMARY
ACTIVE MOIETY
SECUKINUMAB
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966